ArticleAmerican journal of translational research2026
Short-term efficacy of nebulized budesonide for allergic airway inflammation in young children and dynamic changes in fractional exhaled nitric oxide (FeNO): a retrospective cohort study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic airway inflammation in young children with recurrent wheezing may precede asthma. Fractional exhaled nitric oxide (FeNO) may reflect type 2 airway inflammation.
objectiveTo evaluate the short-term effectiveness and safety of nebulized budesonide and dynamic FeNO changes in children aged 6 to 36 months.
methodsWe retrospectively analyzed 548 children treated between January 2023 and February 2025, with follow-up through June 2025. Children receiving standard care plus nebulized budesonide (n = 286) were compared to those on standard care alone (n = 262). Outcomes included clinical response, symptom-resolution time, serial FeNO, inflammatory biomarkers, three-month recurrence and adverse events.
resultsOverall response at day 7 was higher with budesonide than in the control group (92.7% vs. 80.9%; χ
conclusionNebulized budesonide added to standard care was associated with improved short-term clinical outcome, greater FeNO reduction, and lower three-month recurrence in young children with allergic airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.